Agile Therapeutics, Inc. (AGRX)

Agile Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	19.59	10.88	4.1	0.75	0
Revenue Growth (YoY)	80.02%	165.40%	447.53%	-	-
Cost of Revenue	8.98	6.84	10.72	0.28	0.16
Gross Profit	10.62	4.05	-6.62	0.47	-0.16
Selling, General & Admin	28.27	42.23	58.14	36.02	9
Research & Development	2.23	3.25	6.25	13.5	9.86
Other Operating Expenses	0	4.29	-5.3	0	0
Operating Expenses	30.5	45.48	64.39	49.52	18.86
Operating Income	-19.88	-41.43	-71.01	-49.05	-18.86
Interest Income	0.08	0.08	0.03	0.31	0.25
Interest Expense	1.42	3.13	3.91	3.11	0
Other Expense / Income	-8.18	-14.4	-	-	-
Pretax Income	-14.47	-30.09	-74.89	-51.85	-18.61
Income Tax	1.42	-4.68	1.69	2.83	-0.16
Net Income	-14.47	-25.41	-76.59	-54.69	-18.44
Shares Outstanding (Basic)	2	0	0	0	0
Shares Outstanding (Diluted)	2	0	0	0	0
Shares Change	398.99%	35520.10%	-97.13%	71.31%	44.06%
EPS (Basic)	-6.71	-58.79	-63115.49	-1291.56	-746.20
EPS (Diluted)	-6.71	-58.79	-63115.49	-1291.56	-746.20
Free Cash Flow	-9.58	-36.08	-65.47	-47.66	-15.79
Free Cash Flow Per Share	-4.44	-83.48	-53956.18	-1125.72	-638.74
Gross Margin	54.18%	37.19%	-161.35%	62.35%	-
Operating Margin	-101.49%	-380.69%	-1731.41%	-6549.13%	-
Profit Margin	-73.83%	-233.48%	-1867.47%	-7301.20%	-
Free Cash Flow Margin	-48.88%	-331.50%	-1596.46%	-6363.68%	-
EBITDA	-19.42	-41.35	-70.98	-48.74	-18.61
EBITDA Margin	-99.12%	-379.95%	-1730.80%	-6507.88%	-
Depreciation & Amortization	0.39	1.53	2.22	0.28	0.16
EBIT	-19.81	-42.89	-73.2	-49.02	-18.77
EBIT Margin	-101.09%	-394.05%	-1785.00%	-6544.73%	-

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.